Cargando…
S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY
Autores principales: | Ondrisova, Laura, Seda, Vaclav, Hoferkova, Eva, Chiodin, Giorgia, Hlavac, Krystof, Kostalova, Lenka, Filip, Daniel, Faria Zeni, Pedro, Panovska, Anna, Plevova, Karla, Pospisilova, Sarka, Simkovic, Martin, Vrbacky, Filip, Lysak, Daniel, Fernandes, Stacey M., Davids, Matthew S., Maiques-Diaz, Alba, Charalampopoulou, Stella, Martin-Subero, Jose I, Brown, Jennifer R, Doubek, Michael, Forconi, Francesco, Mayer, Jiri, Mraz, Marek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428416/ http://dx.doi.org/10.1097/01.HS9.0000967480.82284.34 |
Ejemplares similares
-
In Vitro and In Vivo Models of CLL–T Cell Interactions: Implications for Drug Testing
por: Hoferkova, Eva, et al.
Publicado: (2022) -
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies
por: Ondrisova, Laura, et al.
Publicado: (2020) -
Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
por: Olbertova, Helena, et al.
Publicado: (2022) -
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022) -
Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options
por: Malcikova, Jitka, et al.
Publicado: (2021)